Angeles Garcia Pardo

List of Publications by Year
in descending order

51 papers	2,834 citations	186265 28 h-index	189892 50 g-index
51 all docs	51 docs citations	51 times ranked	2593 citing authors

#	Article	IF	Citations
1	Î±4Î²1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling. Blood Advances, 2019, 3, 2144-2148.	5.2	8
2	Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways. Biochemical and Biophysical Research Communications, 2015, 461, 243-248.	2.1	12
3	Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochemical Journal, 2015, 465, 259-270.	3.7	39
4	Matrix Metalloproteinase-9 Is Involved in Chronic Lymphocytic Leukemia Cell Response to Fludarabine and Arsenic Trioxide. PLoS ONE, 2014, 9, e99993.	2.5	10
5	Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. Journal of Leukocyte Biology, 2014, 96, 185-199.	3.3	23
6	A Novel CD44-binding Peptide from the Pro-Matrix Metalloproteinase-9 Hemopexin Domain Impairs Adhesion and Migration of Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Biological Chemistry, 2014, 289, 15340-15349.	3.4	30
7	Sphingosineâ€1â€phosphate activates chemokineâ€promoted myeloma cell adhesion and migration involving Î±4Î²1 integrin function. Journal of Pathology, 2013, 229, 36-48.	4.5	30
8	The dioxin receptor controls Î²1 integrin activation in fibroblasts through a Cbpâ€“Cskâ€“Src pathway. Cellular Signalling, 2013, 25, 848-859.	3.6	27
9	A 17-residue Sequence from the Matrix Metalloproteinase-9 (MMP-9) Hemopexin Domain Binds Î±4Î²1 Integrin and Inhibits MMP-9-induced Functions in Chronic Lymphocytic Leukemia B Cells. Journal of Biological Chemistry, 2012, 287, 27601-27613.	3.4	30
10	Molecular and Functional Characterization of Mouse S5D-SRCRB: A New Group B Member of the Scavenger Receptor Cysteine-Rich Superfamily. Journal of Immunology, 2011, 186, 2344-2354.	0.8	19
11	VEGF/VEGFR2 interaction down-regulates matrix metalloproteinaseâ€“9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood, 2010, 115, 846-849.	1.4	29
12	The CS1 segment of fibronectin is involved in human OSCC pathogenesis by mediating OSCC cell spreading, migration, and invasion. BMC Cancer, 2010, 10, 330.	2.6	20
13	Matrix Metalloproteinase-9 Promotes Chronic Lymphocytic Leukemia B Cell Survival through Its Hemopexin Domain. Cancer Cell, 2010, 17, 160-172.	16.8	138
14	Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation. Clinical Cancer Research, 2010, 16, 4382-4391.	7.0	49
15	Inadequate Activation of the GTPase RhoA Contributes to the Lack of Fibronectin Matrix Assembly in von Hippel-Lindau Protein-defective Renal Cancer Cells. Journal of Biological Chemistry, 2008, 283, 24982-24990.	3.4	14
16	Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood, 2008, 111, 383-386.	1.4	90
17	Î±4Î²1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood, 2008, 112, 169-178.	1.4	140
18	The heparin III-binding domain of fibronectin (III4â€“5 repeats) binds to fibronectin and inhibits fibronectin matrix assembly. Matrix Biology, 2007, 26, 642-651.	3.6	25

#	Article	IF	Citations
19	MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by Î±4Î²1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood, 2006, 108, 3143-3151.	1.4	143
20	Activation pathways of Î±4Î²1 integrin leading to distinct T-cell cytoskeleton reorganization, Rac1 regulation and Pyk2 phosphorylation. Journal of Cellular Physiology, 2006, 207, 746-756.	4.1	15
21	AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-ÎºB survival pathway. Leukemia, 2005, 19, 572-579.	7.2	43
22	Heparin II Domain of Fibronectin Uses Î±4Î²1 Integrin to Control Focal Adhesion and Stress Fiber Formation, Independent of Syndecan-4. Journal of Biological Chemistry, 2005, 280, 6915-6922.	3.4	40
23	Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochemical and Biophysical Research Communications, 2004, 315, 562-567.	2.1	36
24	Involvement of p53 in Î±4Î²1 integrin-mediated resistance of B-CLL cells to fludarabine. Biochemical and Biophysical Research Communications, 2003, 311, 708-712.	2.1	37
25	Î±4Î²1 Integrin/Ligand Interaction Inhibits Î±5Î²1-induced Stress Fibers and Focal Adhesions via Down-Regulation of RhoA and Induces Melanoma Cell Migration. Molecular Biology of the Cell, 2003, 14, 3699-3715.	2.1	30
26	A synthetic peptide from the heparin-binding domain III (repeats III4-5) of fibronectin promotes stress-fibre and focal-adhesion formation in melanoma cells. Biochemical Journal, 2003, 371, 565-571.	3.7	17
27	Adhesion to fibronectin viaÎ±4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors. Clinical and Experimental Immunology, 2002, 127, 455-462.	2.6	23
28	Response to Auer: the class II tumor-suppressor gene RARRES3 is expressed in B-CLL and down-regulated with disease progression. Leukemia, 2002, 16, 1396-1397.	7.2	1
29	Reply to Auer. Leukemia, 2002, 16, 1397-1397.	7.2	0
30	The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic leukemias and down-regulated with disease progression. Leukemia, 2001, 15, 1521-1526.	7.2	29
31	Liver Damage using Suicide Genes. American Journal of Pathology, 2000, 157, 549-559.	3.8	35
32	Cooperative Role for Activated Î±4Î²1 Integrin and Chondroitin Sulfate Proteoglycans in Cell Adhesion to the Heparin III Domain of Fibronectin. Journal of Biological Chemistry, 1999, 274, 135-142.	3.4	41
33	Fibronectin interaction with Î±4Î²1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia, 1999, 13, 266-274.	7.2	133
34	Fibronectin Type III5 Repeat Contains a Novel Cell Adhesion Sequence, KLDAPT, Which Binds Activated Î±4Î²1 and Î±4Î²7 Integrins. Journal of Biological Chemistry, 1997, 272, 24832-24836.	3.4	64
35	Analysis of the activation state of Î±4Î²1 integrin in human B cell lines derived from myeloma, leukemia or lymphoma. FEBS Letters, 1997, 418, 337-340.	2.8	9
36	The Î±4Î²1 Fibronectin Ligands CS-19 HEP II, and RGD Induce Different Intracellular Events in B Lymphoid Cells. Comparison with the Effects of the Endothelial Ligand V CAM-1. Cell Adhesion and Communication, 1996, 4, 251-267.	1.7	15

#	Article	IF	Citations
37	Activation of the alpha 4 beta 1 integrin through the beta 1 subunit induces recognition of the RGDS sequence in fibronectin.. Journal of Cell Biology, 1994, 126, 271-279.	5.2	91
38	Further Characterization of the Binding of Fibronectin to Gelatin Reveals the Presence of Different Binding Interactions. Archives of Biochemistry and Biophysics, 1993, 304, 181-188.	3.0	11
39	VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion.. Journal of Experimental Medicine, 1992, 175, 1739-1747.	8.5	121
40	Two novel monoclonal antibodies to fibronectin that recognize the hep II and CS-1 regions respectively: Their differential effect on lymphocyte adhesion. Biochemical and Biophysical Research Communications, 1992, 186, 135-142.	2.1	10
41	Structure-function analysis of the human integrin VLA-4 (Î±4/Î²1). FEBS Letters, 1991, 294, 121-124.	2.8	18
42	Phorbol ester-induced differentiation of U937 cells enhances attachment to fibronectin and distinctly modulates the Î±5Î²1 and Î±4Î²1 fibronectin receptors. Experimental Cell Research, 1991, 193, 20-26.	2.6	54
43	Differential expression of VLA-4 integrin by resident and peripheral blood B lymphocytes. Acquisition of functionally active Î±4Î²1-fibronectin receptors upon B cell activation. European Journal of Immunology, 1991, 21, 2437-2445.	2.9	52
44	Specific binding of the human monocytic cell line U937 to the alternatively spliced connecting segment (IIICS) of fibronectin.. Journal of Experimental Medicine, 1990, 171, 351-356.	8.5	28
45	Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.. Journal of Cell Biology, 1989, 109, 1321-1330.	5.2	794
46	Fibronectin receptors of mononuclear phagocytes: Binding characteristics and biochemical isolation. Experimental Cell Research, 1989, 181, 420-431.	2.6	38
47	Fibronectin binds to amyloid P component. Localization of the binding site to the 31,000 dalton C-terminal domain. Biochemical and Biophysical Research Communications, 1986, 140, 12-20.	2.1	20
48	Primary structure of human plasma fibronectin â€" Characterization of the 6,000 dalton C-terminal fragment containing the interchain disulfide bridges. Biochemical and Biophysical Research Communications, 1984, 120, 1015-1021.	2.1	16
49	Chemical modification of carboxyl groups in human fcÎ³ fragmentâ€"II. Location of acidic residues involved in complement activation. Molecular Immunology, 1982, 19, 579-588.	2.2	17
50	Secretory component is covalently bound to a single sub-unit in human secretory IgA. Molecular Immunology, 1979, 16, 477-482.	2.2	38
51	Subtilisin and cyanogen bromide cleavage products of fibronectin that retain gelatin-binding activity.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 4803-4807.	7.1	82